- Home
- AXSM vs SRRK Comparison
AXSM vs SRRK Comparison
Compare AXSM & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXSM
- SRRK
- Stock Information
- Founded
- AXSM 2012
- SRRK 2012
- Country
- AXSM United States
- SRRK United States
- Employees
- AXSM N/A
- SRRK N/A
- Industry
- AXSM Biotechnology: Pharmaceutical Preparations
- SRRK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AXSM Health Care
- SRRK Health Care
- Exchange
- AXSM Nasdaq
- SRRK Nasdaq
- Market Cap
- AXSM 4.2B
- SRRK 4.2B
- IPO Year
- AXSM 2015
- SRRK 2018
- Fundamental
- Price
- AXSM $137.75
- SRRK $37.70
- Analyst Decision
- AXSM Strong Buy
- SRRK Strong Buy
- Analyst Count
- AXSM 14
- SRRK 7
- Target Price
- AXSM $158.93
- SRRK $40.43
- AVG Volume (30 Days)
- AXSM 1.1M
- SRRK 771.2K
- Earning Date
- AXSM 02-18-2025
- SRRK 02-27-2025
- Dividend Yield
- AXSM N/A
- SRRK N/A
- EPS Growth
- AXSM N/A
- SRRK N/A
- EPS
- AXSM N/A
- SRRK N/A
- Revenue
- AXSM $385,693,000.00
- SRRK N/A
- Revenue This Year
- AXSM $45.18
- SRRK N/A
- Revenue Next Year
- AXSM $65.22
- SRRK N/A
- P/E Ratio
- AXSM N/A
- SRRK N/A
- Revenue Growth
- AXSM 42.53
- SRRK N/A
- 52 Week Low
- AXSM $64.11
- SRRK $6.76
- 52 Week High
- AXSM $139.13
- SRRK $46.98
- Technical
- Relative Strength Index (RSI)
- AXSM 74.55
- SRRK 41.93
- Support Level
- AXSM $124.04
- SRRK $35.35
- Resistance Level
- AXSM $130.52
- SRRK $38.61
- Average True Range (ATR)
- AXSM 5.78
- SRRK 1.80
- MACD
- AXSM 1.11
- SRRK -0.16
- Stochastic Oscillator
- AXSM 96.07
- SRRK 34.20
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.